| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Peptides | Endocrine System |
Recent Updates
Recently added Catalysts
Kailera Therapeutics, Inc.
$18.32
+0.49 (+2.75%)
C 56Pipeline Score Fair Value Biotech · Clinical
Market Cap
2.37 B
EPS
-
P/E Ratio
-
Value Trade
5.20 M
-1.45 %
Week
2.29 %
1 Month
-8.72 %
3 Month
-29.54 %
6 Month
-20.11 %
5 Year
-20.11 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
2.08 M
52 Week Range
19.01 - 28.23
% held by Insiders
33.15 %
% held by Institutions
43.31 %
Enterprise Value
1.20 B
Total Shares
129.57 M
Short %
7.65 %
Float Shares
117.95 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kailera Therapeutics, Inc.
10Total events
6Upcoming
5Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
●IND SubmissionRibupatideIND
Subscribe to view catalyst details
TBD
▲Enrollment CompleteRibupatideTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C56
Pipeline Score $3.7B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.6x
rNPV / MCap Top 87%
Small Cap (rank 122 of 931)
Percentile RankKailera Therapeutics, Inc. carries a moderate pipeline score (56/100), with $5.7B risk-adjusted pipeline value, led by Ribupatide in Obesity (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ribupatide Small molecule | Obesity | Phase 3 | NCT07284875 | 53% | $2.6B | RECRUITING | 3,540 | VERY_FAST | B (68) | Mar 1, 2028 | - | MEDIUM Jul 22, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HRS-7535/KAI-7535 | obesity/overweight and type 2 diabetes | Phase 3 | 2026-07-07 | mean weight loss of up to 10.9% at Week 44; mean weight loss of up to 11.1% at Week 50; lowered HbA1c by an average of 1.50% to 1.68% Read More | Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 Read More | |
HRS-7535/KAI-7535 | obesity/overweight and type 2 diabetes | Phase 3 | 2026-07-07 | mean weight loss of up to 10.9% at Week 44; mean weight loss of up to 11.1% at Week 50; lowered HbA1c by an average of 1.50% to 1.68% Read More | Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 Read More | |
HRS-7535/KAI-7535 | obesity/overweight and type 2 diabetes | Phase 3 | 2026-07-07 | mean weight loss of up to 10.9% at Week 44; mean weight loss of up to 11.1% at Week 50; lowered HbA1c by an average of 1.50% to 1.68% Read More | Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KLRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KLRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KLRAKailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kailera has reported its financial results for Q2 2026, highlighting significant advancements in its ribupatide program. The company has submitted an IND for an oral formulation of ribupatide to the U.S. FDA and plans to initiate global Phase 3 obesity trials in the first half of 2027. Additionally, the Phase 2b high-dose trial for ribupatide injection is fully enrolled, with data expected in mid-2027. The executive team has also been expanded to enhance technical operations.
Read more →KLRAKailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Kailera Therapeutics has appointed Nur Nicholson as Chief Technology Officer to lead its manufacturing and supply chain strategy. This move comes as the company aims to advance its late-stage obesity pipeline towards commercialization. Nicholson's extensive experience in technical operations is expected to bolster the company's efforts in this area.
Read more →KLRAKailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535
Kailera Therapeutics announced positive topline results from two Phase 3 trials of HRS-7535, an oral GLP-1 receptor agonist. In the obesity trial, participants achieved up to 10.9% weight loss, while the diabetes trial showed significant reductions in HbA1c. Safety findings were consistent, with no liver safety signals reported. Kailera is also conducting a global Phase 2 trial to further optimize KAI-7535's profile.
Read more →KLRAKailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Kailera Therapeutics has appointed Kathleen Tregoning as Chief Corporate Affairs Officer. Tregoning, who has extensive experience in corporate affairs within the biopharmaceutical sector, will help navigate the complexities of the obesity treatment landscape. Her role will focus on stakeholder engagement and supporting innovation in obesity care as the company advances its clinical trials.
Read more →KLRAKailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Kailera Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4. CEO Ron Renaud will discuss the company's innovative pipeline focused on obesity care, including their lead candidate, ribupatide injection, currently in Phase 3 trials. The presentation will be available via live webcast and archived for 90 days.
Read more →KLRAKailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates • Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline • Initiat
Kailera Therapeutics has reported its first quarter 2026 financial results, highlighting important advances in its clinical pipeline targeting obesity. The company initiated five late-stage global trials, including the KaiNETIC Phase 3 program for ribupatide injection. Additionally, positive clinical data was reported from trials in collaboration with their partner Hengrui in China, showcasing the potential of various compounds in development. With sufficient cash reserves to fund operations until mid-2028, Kailera aims to maintain momentum in advancing its diverse portfolio of therapies.
Read more →KLRAKailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kailera Therapeutics has successfully closed its initial public offering, raising $718.8 million by offering 44,921,875 shares, including additional shares purchased by underwriters. The IPO was priced at $16.00 per share and is now listed on the Nasdaq under the ticker KLRA. The offering was managed by several prominent financial institutions.
Read more →KLRAKailera Therapeutics Announces Pricing of Initial Public Offering
Kailera Therapeutics has announced the pricing of its initial public offering, offering 39,062,500 shares at $16.00 each. The gross proceeds from this offering are projected to be $625 million, with trading set to begin on the Nasdaq under the ticker KLRA on April 17, 2026. The offering is expected to close on April 20, 2026, pending customary conditions.
Read more →Competitive Position
How KLRA ranks across every disease it competes inCompetitive Position is a premium feature
See how KLRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial